Medroxyprogesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression

Stephen N. Birrell, David M. Roder, David J. Horsfall, Jacqueline M. Bentel, Wayne D. Tilley

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Purpose: To determine the predictive value of androgen receptor (AR) levels in primary tumors of women who undergo medroxyprogesterone acetate (MPA) therapy for advanced breast cancer after relapse on tamoxifen adjuvant therapy. Methods: Between 1984 and 1987 at Flinders Medical Centre, South Australia, 136 postmenopausal women received adjuvant tamoxifen therapy for lymph node-positive breast cancer. Estrogen receptor (ER), progesterone receptor (PgR), and AR levels, tumor size, and degree of axillary node involvement were determined at the time of diagnosis. The median follow-up period was 81 months; 89 women developed metastatic disease, 83 of whom subsequently received MPA (500 mg/d). The objective response rate ([RR] ie, complete response [CR] and partial response [PR]) and progression-free interval (PFI) were assessed in response to MPA therapy. Associations between RR, PFI, and primary tumor characteristics including ER, PgR, and AR levels were examined using the Mann-Whitney U test, Kaplan-Meier product-limit estimator, and Cox proportional hazards regression, as appropriate. Results: Thirty-two of 83 patients (38.6%) responded to MPA. RR was significantly associated with the presence of AR (P < .001), but not with other primary tumor characteristics or duration of tamoxifen therapy. After initiation of MPA treatment, PFI increased with increasing concentration of AR in the primary tumor. Conclusion: Response to MPA after adjuvant tamoxifen treatment for lymph node-positive breast cancer was positively associated with AR level in the primary tumor. This finding suggests that MPA action in breast cancer may be mediated in part by the AR.

LanguageEnglish
Pages1572-1577
Number of pages6
JournalJournal of Clinical Oncology
Volume13
Issue number7
DOIs
Publication statusPublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Birrell, Stephen N. ; Roder, David M. ; Horsfall, David J. ; Bentel, Jacqueline M. ; Tilley, Wayne D. / Medroxyprogesterone acetate therapy in advanced breast cancer : The predictive value of androgen receptor expression. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 7. pp. 1572-1577.
@article{31a68920e11545b0a66d337c3a4cc80f,
title = "Medroxyprogesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression",
abstract = "Purpose: To determine the predictive value of androgen receptor (AR) levels in primary tumors of women who undergo medroxyprogesterone acetate (MPA) therapy for advanced breast cancer after relapse on tamoxifen adjuvant therapy. Methods: Between 1984 and 1987 at Flinders Medical Centre, South Australia, 136 postmenopausal women received adjuvant tamoxifen therapy for lymph node-positive breast cancer. Estrogen receptor (ER), progesterone receptor (PgR), and AR levels, tumor size, and degree of axillary node involvement were determined at the time of diagnosis. The median follow-up period was 81 months; 89 women developed metastatic disease, 83 of whom subsequently received MPA (500 mg/d). The objective response rate ([RR] ie, complete response [CR] and partial response [PR]) and progression-free interval (PFI) were assessed in response to MPA therapy. Associations between RR, PFI, and primary tumor characteristics including ER, PgR, and AR levels were examined using the Mann-Whitney U test, Kaplan-Meier product-limit estimator, and Cox proportional hazards regression, as appropriate. Results: Thirty-two of 83 patients (38.6{\%}) responded to MPA. RR was significantly associated with the presence of AR (P < .001), but not with other primary tumor characteristics or duration of tamoxifen therapy. After initiation of MPA treatment, PFI increased with increasing concentration of AR in the primary tumor. Conclusion: Response to MPA after adjuvant tamoxifen treatment for lymph node-positive breast cancer was positively associated with AR level in the primary tumor. This finding suggests that MPA action in breast cancer may be mediated in part by the AR.",
author = "Birrell, {Stephen N.} and Roder, {David M.} and Horsfall, {David J.} and Bentel, {Jacqueline M.} and Tilley, {Wayne D.}",
year = "1995",
doi = "10.1200/JCO.1995.13.7.1572",
language = "English",
volume = "13",
pages = "1572--1577",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

Medroxyprogesterone acetate therapy in advanced breast cancer : The predictive value of androgen receptor expression. / Birrell, Stephen N.; Roder, David M.; Horsfall, David J.; Bentel, Jacqueline M.; Tilley, Wayne D.

In: Journal of Clinical Oncology, Vol. 13, No. 7, 1995, p. 1572-1577.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medroxyprogesterone acetate therapy in advanced breast cancer

T2 - Journal of Clinical Oncology

AU - Birrell, Stephen N.

AU - Roder, David M.

AU - Horsfall, David J.

AU - Bentel, Jacqueline M.

AU - Tilley, Wayne D.

PY - 1995

Y1 - 1995

N2 - Purpose: To determine the predictive value of androgen receptor (AR) levels in primary tumors of women who undergo medroxyprogesterone acetate (MPA) therapy for advanced breast cancer after relapse on tamoxifen adjuvant therapy. Methods: Between 1984 and 1987 at Flinders Medical Centre, South Australia, 136 postmenopausal women received adjuvant tamoxifen therapy for lymph node-positive breast cancer. Estrogen receptor (ER), progesterone receptor (PgR), and AR levels, tumor size, and degree of axillary node involvement were determined at the time of diagnosis. The median follow-up period was 81 months; 89 women developed metastatic disease, 83 of whom subsequently received MPA (500 mg/d). The objective response rate ([RR] ie, complete response [CR] and partial response [PR]) and progression-free interval (PFI) were assessed in response to MPA therapy. Associations between RR, PFI, and primary tumor characteristics including ER, PgR, and AR levels were examined using the Mann-Whitney U test, Kaplan-Meier product-limit estimator, and Cox proportional hazards regression, as appropriate. Results: Thirty-two of 83 patients (38.6%) responded to MPA. RR was significantly associated with the presence of AR (P < .001), but not with other primary tumor characteristics or duration of tamoxifen therapy. After initiation of MPA treatment, PFI increased with increasing concentration of AR in the primary tumor. Conclusion: Response to MPA after adjuvant tamoxifen treatment for lymph node-positive breast cancer was positively associated with AR level in the primary tumor. This finding suggests that MPA action in breast cancer may be mediated in part by the AR.

AB - Purpose: To determine the predictive value of androgen receptor (AR) levels in primary tumors of women who undergo medroxyprogesterone acetate (MPA) therapy for advanced breast cancer after relapse on tamoxifen adjuvant therapy. Methods: Between 1984 and 1987 at Flinders Medical Centre, South Australia, 136 postmenopausal women received adjuvant tamoxifen therapy for lymph node-positive breast cancer. Estrogen receptor (ER), progesterone receptor (PgR), and AR levels, tumor size, and degree of axillary node involvement were determined at the time of diagnosis. The median follow-up period was 81 months; 89 women developed metastatic disease, 83 of whom subsequently received MPA (500 mg/d). The objective response rate ([RR] ie, complete response [CR] and partial response [PR]) and progression-free interval (PFI) were assessed in response to MPA therapy. Associations between RR, PFI, and primary tumor characteristics including ER, PgR, and AR levels were examined using the Mann-Whitney U test, Kaplan-Meier product-limit estimator, and Cox proportional hazards regression, as appropriate. Results: Thirty-two of 83 patients (38.6%) responded to MPA. RR was significantly associated with the presence of AR (P < .001), but not with other primary tumor characteristics or duration of tamoxifen therapy. After initiation of MPA treatment, PFI increased with increasing concentration of AR in the primary tumor. Conclusion: Response to MPA after adjuvant tamoxifen treatment for lymph node-positive breast cancer was positively associated with AR level in the primary tumor. This finding suggests that MPA action in breast cancer may be mediated in part by the AR.

UR - http://www.scopus.com/inward/record.url?scp=0029055265&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.7.1572

DO - 10.1200/JCO.1995.13.7.1572

M3 - Article

VL - 13

SP - 1572

EP - 1577

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -